2021
Heart Watch Study: protocol for a pragmatic randomised controlled trial
Dhruva SS, Shah ND, Vemulapalli S, Deshmukh A, Beatty AL, Gamble GM, Freeman JV, Hummel JP, Piccini JP, Akar JG, Ervin K, Arges KL, Emanuel L, Noseworthy PA, Hu T, Bartlett V, Ross JS. Heart Watch Study: protocol for a pragmatic randomised controlled trial. BMJ Open 2021, 11: e054550. PMID: 35234659, PMCID: PMC8719216, DOI: 10.1136/bmjopen-2021-054550.Peer-Reviewed Original ResearchMeSH KeywordsAtrial FibrillationAtrial FlutterElectric CountershockHumansMulticenter Studies as TopicPragmatic Clinical Trials as TopicProspective StudiesQuality of LifeRandomized Controlled Trials as TopicConceptsHealthcare utilisationSecondary outcomesAtrial fibrillationAtrial flutterDuke University Health SystemRoutine clinical care settingsAtrial Fibrillation EffectLife global scoresTime of cardioversionAdditional secondary outcomesPopulation of patientsPatient-reported outcomesClinical care settingsUniversity Health SystemQuality of lifeInstitutional review boardMulticentre pragmaticPeer-reviewed journalsPrimary outcomePatients' qualityTrial protocolClinical trialsMayo ClinicECG featuresCare settings
2016
Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL
Freeman JV, Hutton DW, Barnes GD, Zhu RP, Owens DK, Garber AM, Go AS, Hlatky MA, Heidenreich PA, Wang PJ, Al-Ahmad A, Turakhia MP. Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL. Circulation Arrhythmia And Electrophysiology 2016, 9: e003407. PMID: 27307517, PMCID: PMC4911813, DOI: 10.1161/circep.115.003407.Peer-Reviewed Original ResearchConceptsLAA closureLeft atrial appendageQuality-adjusted life yearsPROTECT AFAtrial fibrillationPercutaneous closureWatchman deviceAtrial appendageLife yearsTrial dataWATCHMAN LAA closure devicePROTECT AF trialIncremental cost-effectiveness ratioMajor adverse eventsPrevention of strokeAtrial appendage closureProspective Randomized EvaluationLAA closure deviceLong-term trial resultsQuality-adjusted survivalCost-effectiveness ratioCost-effectiveness resultsMedical anticoagulationAF trialAdverse events
2012
Effectiveness of Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy in Heart Failure
Freeman JV, Masoudi FA. Effectiveness of Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy in Heart Failure. Heart Failure Clinics 2012, 9: 59-77. PMID: 23168318, DOI: 10.1016/j.hfc.2012.09.006.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedCardiac Resynchronization TherapyComparative Effectiveness ResearchDefibrillators, ImplantableDisease ManagementFemaleHeart FailureHumansMaleMeta-Analysis as TopicMiddle AgedObservationOutcome and Process Assessment, Health CarePatient SelectionPractice Guidelines as TopicRandomized Controlled Trials as TopicSecondary PreventionSeverity of Illness IndexSex FactorsSurvival RateConceptsCardiac resynchronization therapyTrial dataResynchronization therapyQRS morphologyNYHA class IV patientsCardiac devicesBenefit of ICDSingle-chamber ICDClass IV patientsHigh-volume hospitalsOptimal medical managementEffective treatment modalityPrior ventricular arrhythmiasProlonged QRS complexRecent trial dataRecent trial resultsImplantable cardioverter defibrillatorQuality of lifeHF hospitalizationSymptomatic HFHF symptomsICD therapySevere comorbiditiesIV patientsMortality benefit